EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 / No 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1026-1028 References
Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1026 - 1028
Section Les anticorps dans les maladies autres qu’oncologiques
DOI https://doi.org/10.1051/medsci/2019203
Published online 06 January 2020
  1. Avis de la commission de transparence - Hemlibra (émicizumab). http://www.roche.fr/content/dam/roche_france/fr_FR/doc/Produits/Hemlibra/Hemlibra_Col_11-07-2018.pdf. Accès au site 12/01/2019. [Google Scholar]
  2. Cryvista (burosumab). Résumé des caractéristiques du produit. https://www.ema.europa.eu/documents/product-information/crysvita-epar-product-information_fr.pdf. [Google Scholar]
  3. Repatha. Arrêté du 8 février 2018 modifiant la liste des spécialités pharmaceutiques remboursables aux assurés sociaux. Legifrance. https://www.legifrance.gouv.fr/eli/arrete/2018/2/8/SSAS1801874A/jo/texte/fr. [Google Scholar]
  4. Praluent. Arrêté du 19 janvier 2018 modifiant la liste des spécialités pharmaceutiques agréées à l’usage des collectivités et divers services publics. Legifrance. https://www.legifrance.gouv.fr/eli/arrete/2018/1/19/SSAS1801114A/jo/texte/fr. [Google Scholar]
  5. Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 2017 ; 18: 832–842. [CrossRef] [PubMed] [Google Scholar]
  6. Georgin-Lavialle S, Rodrigues F, Hentgen V, et al. Clinical overview of auto-inflammatory diseases. Rev Med Interne 2018 ; 39: 214–232. [CrossRef] [PubMed] [Google Scholar]
  7. Avis de la commission de transparence - ILARIS (canakinumab). https://www.has-sante.fr/portail/upload/docs/evamed/CT-16220_ILARIS_PIC_EI_Avis3_CT16220.pdf. [Google Scholar]
  8. Akgul O, Kilic E, Kilic G, et al. Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci 2013 ; 346: 137–141. [Google Scholar]
  9. Georgin-Lavialle S, Hentgen V, Stankovic Stojanovic K, et al. Familial Mediterranean fever. Rev Med Interne 2018 ; 39: 240–255. [CrossRef] [PubMed] [Google Scholar]
  10. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 2013 ; 43: 387–391. [CrossRef] [PubMed] [Google Scholar]
  11. Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet 2017 ; 390: 681–696. [CrossRef] [PubMed] [Google Scholar]
  12. Goodship THJ, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 2017 ; 91: 539–551. [CrossRef] [PubMed] [Google Scholar]
  13. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998 ; 53: 836–844. [CrossRef] [PubMed] [Google Scholar]
  14. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013 ; 8: 554–562. [CrossRef] [PubMed] [Google Scholar]
  15. Avis de la commission de transparence - soliris (eculizumab). https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/soliris_19092012_avis_ct12290.pdf. [Google Scholar]
  16. Brachet G, Bourquard T, Gallay N, et al. Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action. Mol Immunol 2016 ; 77: 126–131. [Google Scholar]
  17. Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. mAbs 2015; 7: 1205–11. [CrossRef] [PubMed] [Google Scholar]
  18. A randomized, double-blind, single-dose, 3-arm, parallel group study to determine the pharmacokinetic similarity of ABP 959 and Eculizumab (Soliris Registered Trademark) in healthy male subjects. ACTRN12616000509460 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369851. [Google Scholar]
  19. Ricklin D, Mastellos DC, Reis ES, et al. The renaissance of complement therapeutics. Nat Rev Nephrol 2018 ; 14: 26–47. [CrossRef] [PubMed] [Google Scholar]
  20. Safety and efficacy study of OMS721 in patients with atypical hemolytic uremic syndrome. https://clinicaltrials.gov/ct2/show/NCT03205995. [Google Scholar]
  21. Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 2017 ; 376: 717–728. [Google Scholar]
  22. Atu-Takhzyro (lanadelumab). https://ansm.sante.fr/var/ansm_site/storage/original/application/aacfb94a0608503e6bb38250904ced7f.pdf. [Google Scholar]
  23. Francis F, Hennig S, Korn B, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets. Nat Genet 1995 ; 11: 130. [Google Scholar]
  24. White KE, Evans WE, O’Riordan JLH, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000 ; 26: 345–348. [Google Scholar]
  25. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004 ; 19: 429–435. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.